Cue Biopharma initiated an investigator-sponsored trial at Dana-Farber Cancer Institute for glioblastoma multiforme.
1 report, 1 independent
Updated Aug 13
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cue Biopharma initiated an investigator-sponsored trial at Dana-Farber Cancer Institute for glioblastoma multiforme.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Dana–Farber Cancer Institute
hospital in Massachusetts, United States
Nothing else this week.
-
Reardon
(born 1949)
Nothing else this week.
Coverage
Newest first; wire copies grouped- GlobeNewswireCue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme First patient dosed with CUE-102 for recurrent glioblastoma multiforme (rGBM) at Dan